Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Affiliations

Science Blogs
ACI Profile for Alan Kotok
Featured in Alltop

Health Insurance Group Forms Academic Research Network

The national organization of Blue Cross-Blue Shield health insurance providers is linking up with academic researchers to study outcomes of health care practices, including opioid abuse and cancer screenings. . . . → Read More: Health Insurance Group Forms Academic Research Network

Breast Cancer Drug Costs Vary Among Insured Patients

Women receiving chemotherapy for breast cancer can face widely different costs for their treatments, regardless of effectiveness, even if they have health insurance. . . . → Read More: Breast Cancer Drug Costs Vary Among Insured Patients

Malnutrition Shown Adding Billions to U.S. Health Costs

An analysis of data from health surveys shows malnutrition associated with 8 common chronic diseases adds $15.5 billion directly to U.S. health care costs. . . . → Read More: Malnutrition Shown Adding Billions to U.S. Health Costs

Drug Reconciliation Program Cuts Hospital Readmission

Consultations with pharmacists on medications when patients leave the hospital for home are shown to reduce the rate of readmission to the hospital by half. . . . → Read More: Drug Reconciliation Program Cuts Hospital Readmission

More Device Approvals, Higher Risks in Europe than U.S.

(PublicDomainPictures, Pixabay)

29 June 2016. An analysis of regulatory approvals and outcomes shows medical devices are reviewed and approved faster in Europe than the U.S., but also face more safety issues later on. A team from Kings College London and Harvard University published its findings yesterday in the journal BMJ.

Researchers led by Aaron . . . → Read More: More Device Approvals, Higher Risks in Europe than U.S.

New Diabetic Eye Disease Drugs Shown Not Cost-Effective

(TBIT/Pixabay)

10 June 2016. An evaluation of two new biologic drugs to treat diabetic macular edema, an eye disease caused by diabetes, show the drugs do not provide enough additional benefit over much less expensive treatments to justify their higher price tags. The team led by Adam Glassman of the Jaeb Center for Health . . . → Read More: New Diabetic Eye Disease Drugs Shown Not Cost-Effective

Kauffman Index Shows Higher Start-Up Growth in 2016

Top 40 metropolitan regions in the U.S. in rate of entrepreneurial growth. (Ewing Marion Kauffman Foundation)

8 June 2016. An index of high-growth start-up companies shows the rate of entrepreneurial expansion in the U.S. accelerated for the third year in a row, with greatest concentration of growing enterprises found in the Washington, D.C. region. . . . → Read More: Kauffman Index Shows Higher Start-Up Growth in 2016

Another Chance to Get Serious on Drug Pricing

Stephen Ubl at National Press Club, 25 May 2016 (A. Kotok)

Stephen Ubl, president and CEO of Pharmaceutical Research and Manufacturers of America, or PhRMA, told a press and industry event in Washington, D.C. on Wednesday (25 May) that drug makers are eager to develop more individualized treatments for patients, but proposed regulations on . . . → Read More: Another Chance to Get Serious on Drug Pricing

Pricing Factors Proposed for Gene Therapies

(NIH.gov)

Updated 27 May 2016. See Another Chance to Get Serious on Drug Pricing.

A pediatric cancer specialist and venture capital executive argue for establishing a framework for pricing gene therapies to treat inherited and other diseases, before these treatments are approved by FDA. Stuart Orkin, a pediatric oncologist and hematologist at Dana-Farber Cancer . . . → Read More: Pricing Factors Proposed for Gene Therapies

Braeburn to Continue N. Carolina Facility Despite HB2

(Boston Public Library, Wikimedia Commons)

17 May 2016. Braeburn Pharmaceuticals, a developer of treatments for opioid addiction, will continue with its plans to build a research and manufacturing facility in North Carolina, despite its opposition to a recent state law overturning local ordinances prohibiting discrimination against the LGBT (Lesbian, Gay, Bisexual and Transgender) individuals. . . . → Read More: Braeburn to Continue N. Carolina Facility Despite HB2